Trump expedites review of psychedelics to treat mental health disorders : NPR

Key Points:

• President Trump signed an executive order directing $50 million in federal funds to increase accessibility to psychedelic drugs like psilocybin and ibogaine for treating mental health conditions, and ordered the FDA to fast-track their review.
• The FDA will issue national priority vouchers for three psychedelics, allowing their review process to be expedited to potentially just weeks, marking the first time psychedelics have been fast-tracked by the agency.
• Trump emphasized psychedelics as a solution to the national mental health crisis, citing over 14 million American adults with serious mental illness and highlighting ongoing trials involving veterans with PTSD.
• Psychedelic drugs, previously researched in the 1950s but halted due to recreational abuse concerns, have shown promising results in recent studies for easing anxiety, depression, and addiction.
• Despite their Schedule I status, which classifies them as having no accepted medical use and high abuse potential, psychedelics like psilocybin and ibogaine are gaining renewed attention for their therapeutic potential.